PRLD
Prelude Therapeutics Incorporated NASDAQ Listed Sep 25, 2020$5.15
After hrs
$4.58
-5.80%
Mkt Cap $287.0M
52w Low $0.75
91.9% of range
52w High $5.54
50d MA $3.79
200d MA $2.16
P/E (TTM)
-3.6x
EV/EBITDA
-1.4x
P/B
5.3x
Debt/Equity
0.3x
ROE
-145.0%
P/FCF
-4.0x
RSI (14)
—
ATR (14)
—
Beta
0.71
50d MA
$3.79
200d MA
$2.16
Avg Volume
347.7K
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
200 Powder Mill Road · Wilmington, DE 19803 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 10, 2026 | AMC | -0.33 | -0.20 | +39.4% | 3.60 | +3.6% | +5.8% | -6.4% | -8.3% | -6.7% | -4.7% | — |
| Nov 12, 2025 | AMC | -0.35 | -0.26 | +25.7% | 1.47 | +0.7% | +2.7% | +3.4% | +12.2% | +14.3% | +13.6% | — |
| Aug 14, 2025 | AMC | -0.45 | -0.41 | +8.9% | 0.94 | -1.6% | -7.9% | -0.1% | -5.5% | +11.1% | +16.4% | — |
| May 6, 2025 | AMC | -0.47 | -0.42 | +10.6% | 0.80 | +0.3% | -4.0% | +2.7% | -1.9% | +10.9% | +25.6% | — |
| Mar 10, 2025 | AMC | -0.49 | -0.38 | +22.4% | 0.67 | +0.4% | -1.3% | +3.9% | +5.5% | +11.2% | +12.7% | — |
| Nov 6, 2024 | AMC | -0.48 | -0.43 | +10.4% | 1.32 | +0.0% | -3.8% | -9.8% | -9.8% | -12.9% | -19.7% | — |
| Aug 12, 2024 | AMC | -0.46 | -0.46 | +0.0% | 4.75 | -1.1% | +30.5% | +8.6% | +21.5% | +9.7% | +23.6% | — |
| May 7, 2024 | AMC | -0.47 | -0.42 | +10.6% | 3.70 | -0.3% | -3.0% | +10.0% | +0.8% | +2.7% | +4.3% | — |
| Feb 15, 2024 | AMC | -0.50 | -0.47 | +6.0% | 3.48 | +0.6% | +33.0% | +19.5% | +8.6% | +11.2% | +13.8% | — |
| Nov 1, 2023 | AMC | -0.58 | -0.45 | +22.4% | 1.86 | -6.5% | +18.8% | +22.0% | +58.6% | +61.8% | +61.3% | — |
| Aug 3, 2023 | AMC | -0.65 | -0.54 | +16.9% | 3.61 | +2.8% | +1.7% | +1.7% | -1.1% | -1.4% | +0.3% | — |
| May 8, 2023 | AMC | -0.68 | -0.58 | +14.7% | 6.37 | +0.6% | -1.7% | +1.4% | +3.0% | +5.7% | +4.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 4 | D. Boral Capital | Initiates | Buy | $9 | $4.70 | $4.82 | +2.6% | +0.9% | -0.6% | +3.0% | +9.6% | — |
| Apr 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.70 | $4.92 | +4.7% | -3.8% | -6.6% | -9.1% | +11.3% | +0.0% |
| Mar 11 | Citizens | Maintains | Market Outperform → Market Outperform | — | $3.60 | $3.73 | +3.6% | +5.8% | -6.4% | -8.3% | -6.7% | -4.7% |
| Sep 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.01 | $1.10 | +8.9% | +2.0% | +15.8% | +20.8% | +48.5% | +35.6% |
| Aug 18 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $0.87 | $0.87 | -0.0% | +8.5% | +2.7% | +20.7% | +26.4% | +42.5% |
| May 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.89 | $0.89 | +0.5% | -7.4% | -10.3% | -13.9% | -7.9% | -12.0% |
| Apr 29 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $0.89 | $0.87 | -1.9% | +1.6% | +8.2% | +3.6% | +0.1% | -7.3% |
| Apr 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.65 | $0.65 | +0.0% | -5.8% | +2.6% | -1.0% | +9.3% | +7.1% |
| Mar 12 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $0.66 | $0.71 | +7.7% | +5.3% | +6.9% | +12.7% | +14.2% | +7.1% |
| Dec 11 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $0.97 | $0.97 | +0.0% | -3.1% | -8.7% | -17.5% | -7.7% | -8.6% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.27 | $1.25 | -1.6% | -6.3% | -6.3% | -9.4% | -16.5% | -18.9% |
| Oct 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.52 | $1.51 | -0.7% | -1.3% | -5.9% | -13.2% | -21.1% | -18.4% |
| Sep 19 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $2.44 | $2.56 | +4.9% | +4.5% | +4.5% | -2.9% | -9.8% | -14.8% |
| Sep 16 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $2.77 | $2.78 | +0.4% | -6.1% | -11.6% | -11.9% | -7.9% | -7.9% |
| Sep 16 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $2.77 | $2.78 | +0.4% | -6.1% | -11.6% | -11.9% | -7.9% | -7.9% |
| Sep 10 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $4.96 | $4.94 | -0.4% | +8.5% | +0.8% | -2.6% | -44.2% | -47.6% |
| Aug 15 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $5.16 | $5.31 | +2.9% | +11.8% | +1.0% | +13.8% | +2.3% | +3.9% |
| Feb 20 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $4.63 | $4.56 | -1.5% | -10.2% | -18.4% | -16.4% | -14.5% | -11.7% |
| Dec 19 | Morgan Stanley | Downgrade | Equal Weight → Underweight | — | $4.37 | $4.11 | -5.9% | -7.6% | -9.2% | -7.1% | -3.7% | -4.3% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.95 | $2.96 | +0.3% | +2.0% | +1.7% | +2.4% | +2.0% | +2.0% |
| Oct 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.38 | $2.41 | +1.3% | -2.5% | +0.4% | -10.1% | -11.3% | -13.0% |
| Aug 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.57 | $3.56 | -0.3% | -3.4% | -7.0% | -6.4% | -7.6% | -3.6% |
| Aug 4 | Barclays | Maintains | Equal Weight → Equal Weight | — | $3.61 | $3.71 | +2.8% | +1.7% | +1.7% | -1.1% | -1.4% | +0.3% |
| Aug 4 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $3.61 | $3.71 | +2.8% | +1.7% | +1.7% | -1.1% | -1.4% | +0.3% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.56 | $6.56 | +0.0% | +2.7% | +2.6% | -9.0% | -7.3% | -1.5% |
| Nov 21 | BofA Securities | Downgrade | Neutral → Underperform | — | $7.44 | $7.06 | -5.1% | -12.2% | -12.8% | -10.3% | -8.3% | -13.7% |
| Nov 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.70 | $7.22 | -6.3% | +1.7% | -3.4% | -15.2% | -15.7% | -13.4% |
| Nov 15 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $7.75 | $7.98 | +3.0% | +0.6% | -0.6% | +1.0% | -4.0% | -15.7% |
| Sep 9 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $7.94 | $7.45 | -6.2% | -2.4% | -2.9% | -1.3% | -5.9% | -5.3% |
| Jul 29 | Jefferies | Maintains | Buy → Buy | — | $5.55 | $5.70 | +2.7% | -9.9% | -9.0% | -5.8% | -1.3% | +3.2% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.04 | $3.99 | -1.2% | +6.7% | +14.4% | +17.1% | +20.5% | +10.1% |
| Mar 17 | Morgan Stanley | Maintains | Overweight → Overweight | — | $7.75 | $7.78 | +0.4% | +7.9% | +8.8% | -4.9% | -4.0% | -5.4% |
| Mar 15 | BofA Securities | Downgrade | Buy → Neutral | — | $7.75 | $7.37 | -4.9% | -7.7% | +0.0% | +7.9% | +8.8% | -4.9% |
| Feb 28 | Barclays | Downgrade | Overweight → Equal Weight | — | $10.39 | $9.61 | -7.5% | -15.0% | -18.5% | -15.9% | -22.6% | -24.4% |
| Nov 17 | Barclays | Maintains | Overweight → Overweight | — | $16.02 | $15.95 | -0.4% | -2.2% | -9.9% | -9.7% | -15.1% | -10.4% |
| Oct 11 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $15.87 | $15.89 | +0.1% | +0.6% | -1.8% | -0.4% | +2.2% | +2.5% |
| Oct 8 | Barclays | Maintains | Overweight → Overweight | — | $17.34 | $17.34 | +0.0% | -8.5% | -7.9% | -10.1% | -8.8% | -6.5% |
| Jul 27 | BofA Securities | Upgrade | Neutral → Buy | — | $33.33 | $35.33 | +6.0% | +4.0% | +4.4% | -1.8% | -3.9% | -4.8% |
| Apr 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.59 | $36.36 | +5.1% | +4.7% | +2.8% | +14.1% | +17.0% | +19.8% |
| Mar 17 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $55.85 | $58.66 | +5.0% | +0.8% | -5.8% | -2.1% | +4.5% | -0.9% |
| Dec 16 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $69.92 | $70.22 | +0.4% | +2.7% | +9.4% | +8.8% | +11.3% | +18.3% |
| Nov 12 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $40.10 | $39.65 | -1.1% | +6.1% | +19.3% | +19.3% | +28.9% | +31.9% |
No insider trades available.
8-K
Prelude Therapeutics Incorporated -- 8-K Filing
Prelude Therapeutics is raising capital through an offering to fund research, clinical development, and working capital needs, extending its cash runway for operations.
Apr 21
8-K
Prelude Therapeutics Incorporated -- 8-K Filing
Prelude Therapeutics' PRT13722 demonstrated superior preclinical efficacy in hormone receptor-positive breast cancer compared to dual inhibitors, showing durable complete tumor regressions as monotherapy at tolerable doses.
Apr 20
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
The appointment of a Chief Medical Officer suggests CLYYF and PRLD are strengthening clinical leadership to advance product development and regulatory strategy, potentially accelerating pipeline progress and reducing execution risk.
Apr 15
8-K
Unknown — 8-K Filing
PRLD's legal opinion confirms securities offering compliance, signaling an imminent registered offering or capital raise that will dilute existing shareholders but provide growth capital.
Mar 12
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Prelude Therapeutics advanced its clinical pipeline with IND clearance for PRT12396, signaling execution progress on strategic programs that could drive near-term catalysts and investor confidence.
Mar 10
8-K · 5.02
!!! Very High
Sana Biotechnology, Inc. -- 8-K 5.02: Executive Change
Sana Biotechnology appointed experienced CFO Piper, previously at Scorpion Therapeutics, as Executive Vice President and Chief Financial Officer, strengthening financial leadership during the company's development stage.
Feb 17
8-K · 7.01
! Medium
Prelude Therapeutics Incorporated -- 8-K 7.01: Regulation FD Disclosure
Prelude Therapeutics gained FDA clearance to initiate Phase 1 testing of PRT12396, a JAK2 inhibitor for myeloproliferative neoplasms, advancing its clinical pipeline and de-risking development efforts.
Feb 3
Data updated apr 26, 2026 8:44pm
· Source: massive.com